A Phase Ib Trial of Pembrolizumab (MK-3475) and Trametinib Focused on Advanced KRAS Mutant Non-small Cell Lung Cancer

Trial Profile

A Phase Ib Trial of Pembrolizumab (MK-3475) and Trametinib Focused on Advanced KRAS Mutant Non-small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Jul 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Trametinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Jul 2018 Status changed from not yet recruiting to recruiting.
    • 28 Feb 2018 Planned initiation date changed from 1 Dec 2017 to 1 Aug 2018.
    • 28 Feb 2018 Status changed from recruiting to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top